Skip to main content
Pherecydes Pharma logo

Pherecydes Pharma — Investor Relations & Filings

Ticker · ALPHE ISIN · FR0011651694 LEI · 894500LYT3UUN58X3I68 PA Professional, scientific and technical activities
Open in API
Filings indexed 146 across all filing types
Latest filing 2021-10-07 Declaration of Voting R…
Country FR France
Listing PA ALPHE

About Pherecydes Pharma

https://www.pherecydes-pharma.com/en/

Pherecydes Pharma is a clinical-stage biotechnology company specializing in the research and development of phage therapy to combat antibiotic-resistant bacterial infections. The company develops targeted treatments using bacteriophages, which are naturally occurring viruses that specifically infect and destroy bacteria. Its therapeutic approach focuses on providing personalized solutions for severe infections, particularly those caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. The company utilizes a proprietary phage bank and a diagnostic tool to determine the most effective phages for each patient's specific bacterial strain. In 2023, Pherecydes Pharma merged with Erytech to form Phaxiam Therapeutics, combining expertise to advance phage therapy as a mainstream anti-infective solution.

Recent filings

Filing Released Lang Actions
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capitalsocial" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares, theoretical voting rights, and actual exercisable voting rights as of a specific date (30/09/2021). This structure is characteristic of mandatory regulatory disclosures concerning the total share capital and voting power, which falls under general regulatory announcements or specific capital structure reporting. Since it is a recurring, mandatory disclosure about the capital structure (shares and voting rights), it is best classified as a general Regulatory Filing (RNS) or potentially related to Share Issue/Capital Change (SHA). However, given the specific nature of reporting voting rights monthly, and the lack of a dedicated code for 'Monthly Voting Rights Report', RNS serves as the most appropriate general regulatory filing category for this type of periodic disclosure that isn't a full financial report (10-K, IR) or a specific transaction (POS, SHA). The length is short, but it is the report itself, not an announcement of a report.
2021-10-07 French
Inside Information / Other news releases
Investor Presentation Classification · 95% confidence The document is a press release titled "Pherecydes Pharma announces its participation in a number of major scientific conferences and investor events in H2 2021". It details a schedule of upcoming investor conferences and scientific symposia where company management will present or participate. This type of announcement, informing investors about management's schedule for engaging with the market and presenting company information at external forums, is best classified as an Investor Presentation (IP) announcement or, more broadly, a general regulatory/investor relations communication. Since it is an announcement about future participation rather than the presentation material itself, and it is not a standard financial report (10-K, IR, ER), it fits best under the category of Investor Presentation (IP) if the content is primarily strategic/financial, or potentially Regulatory Filings (RNS) if it's a general update. Given the focus on investor events and presentations, IP is a strong candidate, but since it's an announcement of *participation* rather than the presentation document itself, and it's a general corporate update, RNS (Regulatory Filings/General Announcement) is often used for such forward-looking scheduling news that doesn't fit a specific financial report code. However, the content is highly relevant to investor engagement. Comparing the options, it is not a formal financial report, earnings release, or management discussion. It is an announcement about investor engagement. If we consider the intent is to inform investors about where they can find management, it aligns closely with Investor Presentation (IP) materials being promoted, or a general announcement (RNS). Given the context of informing about presentations at investor events, IP is plausible, but RNS is the safest fallback for non-standard announcements. Let's re-evaluate based on the definitions. It is not a DEF 14A (Remuneration), DIRS (Director Dealing), or DIV (Dividend). It is an announcement about management engaging with investors/scientists. This is a common type of corporate communication. Since it is not a specific financial report, and it's not a proxy statement (PSI) or management discussion (MDA), RNS (Regulatory Filings/General Announcement) is the most appropriate general category for this type of scheduling news release.
2021-09-08 English
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 95% confidence The document is a press release from Pherecydes Pharma dated September 8, 2021, announcing the management team's participation in several scientific conferences and investor events scheduled for the second half of 2021 (September through November). It lists specific events like Adebiotech, Boston Biotechnology Summit, Séminaire Biotech / Santé Portzamparc, etc., where the company will present or interact with investors. This type of announcement, detailing future corporate participation in industry/investor events, is best classified as an Investor Presentation (IP) announcement or, more broadly, a general corporate update related to investor relations. Since the document itself is an announcement about future participation rather than the presentation material itself, and it doesn't fit the strict definitions of ER, 10-K, or IR, it aligns closely with communications intended for investors about upcoming engagement opportunities. However, given the options, it is a communication detailing future investor/scientific engagement, which is often bundled with Investor Presentations (IP) or treated as a general Regulatory Filing (RNS) if no better fit exists. Since it is an announcement about future investor/scientific engagement, and not a formal financial report, the closest fit among the specific categories related to investor communication is 'Investor Presentation' (IP) if we interpret it as an announcement leading up to investor interactions, or 'Regulatory Filings' (RNS) as a general corporate update. Given the focus on investor events and scientific updates, 'Investor Presentation' (IP) is a plausible fit for the *topic*, but the document is an *announcement* of participation. Since there is no specific code for 'Event Schedule Announcement', and it is a formal press release detailing corporate activities for investors, 'RNS' (Regulatory Filings - general fallback) is often used for such non-financial, forward-looking corporate news releases. However, because the content is entirely focused on events where the company will present its strategy/data to investors, 'IP' (Investor Presentation) is a strong thematic match, even if it's an announcement *about* presentations. I will lean towards RNS as the safest general corporate announcement category, as it is not the presentation itself, nor a formal financial report.
2021-09-08 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital-social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of August 31, 2021. This content directly relates to tracking changes in share capital and voting rights, which aligns with the definition of a Major Shareholding Notification (MRQ) or a general regulatory filing concerning capital structure. Since it is a specific monthly disclosure about the total number of shares and voting rights, it fits best under Major Shareholding Notification (MRQ) as it tracks the base for potential significant ownership changes, although it is a mandatory disclosure for all companies. Given the options, MRQ covers notifications related to share structure changes that impact voting power, making it the most specific fit over the general RNS or SHA (which is more about issuing new shares). The length is short (under 3000 chars), but it is the report itself, not an announcement of a report.
2021-09-06 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Net Asset Value Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capitalsocial" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and references Article 223-16 of the AMF General Regulation. It provides a table showing the total number of shares, theoretical voting rights, and actual voting rights as of a specific date (31/07/2021). This type of regular disclosure concerning the total number of shares and voting rights is a specific regulatory requirement, often related to capital structure updates or mandatory periodic reporting. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it details the composition of the capital and voting rights, it most closely aligns with a Capital/Financing Update (CAP) or, given its specific nature as a mandatory disclosure on share count, it could be considered a specialized regulatory filing. However, among the provided options, it is a direct report on the capital structure, making CAP a strong candidate. If a more specific 'Share Capital Disclosure' existed, it would fit there. Given the options, and recognizing this is a mandatory disclosure about the share base, it fits best under Capital/Financing Update (CAP) as it directly relates to the capital structure, or potentially Regulatory Filings (RNS) if CAP is reserved for active fundraising. Since it is a direct report on the capital structure components (shares and voting rights), CAP is the most appropriate fit over the general RNS fallback.
2021-08-04 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is titled "Bilan semestriel du contrat de liquidité de Pherecydes Pharma" (Semi-annual balance sheet of the liquidity contract of Pherecydes Pharma) and reports on transactions and holdings related to a liquidity contract as of June 30, 2021, covering the first semester (1er semestre) of 2021. This content details financial activity over a six-month period, which aligns with the definition of a comprehensive financial report for a period shorter than a year. Therefore, it should be classified as an Interim / Quarterly Report (IR). Although it is a report on a specific contract, the scope (semestriel/half-year) points strongly to IR rather than a general Regulatory Filing (RNS) or a specific Capital/Financing Update (CAP), as it is a periodic financial disclosure.
2021-07-06 French

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.